

## Publications

LBI members  
2003-2022

---

### Original Articles 2022

- 1. *Aero-allergen sensitization in the general population: Longitudinal analyses of the LEAD (Lung Heart Social Body) Study.***  
Köllli F, Breyer MK, Hartl S, Burghuber O, Wouters EFM, Sigsgaard T, Pohl W, Kohlböck G, Breyer-Kohansal R. *J Asthma Allergy*. 2022 Apr 11;15:461-473. eCollection 2022. IF: 4.258.
- 2. *Comorbidity clusters in patients with moderate-to-severe OSA.***  
Testelmans D, Spruit MA, Vrijsen B, Sastry M, Belge C, Kalkanis A, Gaffron S, Wouters EFM, Buyse B. *Sleep Breath*. 2022 Mar;26(1):195-204. Epub 2021 May 3. IF: 2.816.
- 3. *Differential Outcomes Following 4 Weeks of Acclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study.***  
Koopman M, Franssen FME, Gaffron S, Watz H, Troosters T, Garcia-Aymerich J, Paggiaro P, Molins E, Moya M, van Burk L, Maier D, Garcia Gil E, Wouters EFM, Vanfleteren LEGW, Spruit MA. *Int J Chron Obstruct Pulmon Dis*. 2022;17:517-533. IF: 3.792.
- 4. *Restricted spirometry and cardiometabolic comorbidities: results from the international population based BOLD study***  
Katarzyna Kulbacka-Ortiz, Filip J J Triest, Frits M E Franssen, Emiel F M Wouters, Michael Studnicka, William M Vollmer, Bernd Lamprecht, Peter G J Burney, Andre F S Amaral, Lowie E G W Vanfleteren. *Respir Res*. 2022 Feb 17;23(1):34. IF 4.916.
- 5. *Multidimensional outcome assessment of pulmonary rehabilitation in traits-based clusters of COPD patients.***  
Augustin IML, Franssen FME, Houben-Wilke S, Janssen DJA, Gaffron S, Pennings HJ, Smeenk FWJM, Pieters WR, Hoogerwerf A, Michels AJ, van Merode F, Wouters EFM, Spruit MA. *PLoS One*. 2022 Feb 17;17(2):e0263657. IF: 3.240.
- 6. *Distribution of chronic cough phenotypes in the general population: A cross-sectional analysis of the LEAD cohort in Austria.***  
Abozid H, Baxter CA, Hartl S, Braun E, Salomonsson S, Breyer-Kohansal R, Breyer MK, Wouters EFM, Agusti A, Burghuber OC. *Respir Med*. 2022 Feb;192:106726. IF: 3.415.

7. ***Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies.***

Allinson JP, Afzal S, Çolak Y, Jarvis D, Backman H, van den Berge M, Boezen HM, Breyer MK, Breyer-Kohansal R, Brusselle G, Burghuber OC, Faner R, Hartl S, Lahousse L, Langhammer A, Lundbäck B, Nwaru BI, Rönmark E, Vikjord SAA, Vonk JM, Wijnant SRA, Lange P, Nordestgaard BG, Olvera N, Agusti A, Donaldson GC, Wedzicha JA, Vestbo J, Vanfleteren LEGW; CADSET Clinical Research Collaboration. *Lancet Respir Med.* 2022 Jan;10(1):83-94. IF: 30.700.

## 2021

8. ***Soluble ST2 and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease-A 10-Year Cohort Study.***

Urban MH, Stojkovic S, Demyanets S, Hengstenberg C, Valipour A, Wojta J, Burghuber OC. *J Clin Med.* 2021 Dec 23;11(1):56. IF: 4.242.

9. ***Implementation of Bronchoscopic Lung Volume Reduction Using One-Way Endobronchial Valves: A Retrospective Single-Centre Cohort Study.***

Posthuma R, Vaes AW, Walraven KHM, Sardari Nia P, Schreiber JU, Gietema HA, Wesseling G, Wouters EFM, Vanfleteren LEGW. *Respiration.* 2021 Dec 22:1-9. Online ahead of print. IF: 2.67.

10. ***Spirometric phenotypes from early childhood to young adulthood: a Chronic Airway Disease Early Stratification study.***

Wang G, Hallberg J, Charalampopoulos D, Sanahuja MC, Breyer-Kohansal R, Langhammer A, Granell R, Vonk JM, Mian A, Olvera N, Laustsen LM, Rönmark E, Abellan A, Agusti A, Arshad SH, Bergström A, Boezen HM, Breyer MK, Burghuber O, Bolund AC, Custovic A, Devereux G, Donaldson GC, Duijts L, Esplugues A, Faner R, Ballester F, Garcia-Aymerich J, Gehring U, Haider S, Hartl S, Backman H, Holloway JW, Koppelman GH, Lertxundi A, Holmen TL, Lowe L, Mensink-Bout SM, Murray CS, Roberts G, Hedman L, Schlünssen V, Sigsgaard T, Simpson A, Sunyer J, Torrent M, Turner S, Van den Berge M, Vermeulen RCH, Vikjord SAA, Wedzicha JA, Maitland van der Zee AH, Melén E. *ERJ Open Res.* 2021 Dec 6;7(4):00457-2021. IF: 1.0.

11. ***Reduced Vitamin K Status as a Potentially Modifiable Risk Factor of Severe Coronavirus Disease 2019.***

Dofferhoff ASM, Piscaer I, Schurgers LJ, Visser MPJ, van den Ouweland JMW, de Jong PA, Gosens R, Hackeng TM, van Daal H, Lux P, Maassen C, Karssemeijer EGA, Vermeer C, Wouters EFM, Kistemaker LEM, Walk J, Janssen R. *Clin Infect Dis.* 2021 Dec 6;73(11):e4039-e4046. IF: 4.81.

12. ***Using Body Composition Groups to Identify Children and Adolescents at Risk of Dyslipidemia.***

Ofenheimer A, Breyer-Kohansal R, Hartl S, Burghuber OC, Krach F, Franssen FME, Wouters EFM, Breyer MK. *Children (Basel).* 2021 Nov 13;8(11):1047. IF: 2.863.

13. ***Glutathione-S-transferase P promotes glycolysis in asthma in association with oxidation of pyruvate kinase M2.***  
van de Wetering C, Manuel AM, Sharafi M, Aboushousha R, Qian X, Erickson C, MacPherson M, Chan G, Adcock IM, ZounematKermani N, Schleich F, Louis R, Bohrnsen E, D'Alessandro A, Wouters EF, Reynaert NL, Li J, Wolf CR, Henderson CJ, Lundblad LKA, Poynter ME, Dixon AE, Irvin CG, van der Vliet A, van der Velden JL, Janssen-Heininger YM. Redox Biol. 2021 Nov;47:102160. IF: 11.799.
14. ***Health Literacy Among Patients With Chronic Lung Disease Entering Pulmonary Rehabilitation and Their Resident Loved Ones.***  
Coenjaerds MMJ, Spruit MA, Cleutjens FAHM, Ponds RWHM, Franssen FME, Wouters EFM, Janssen DJA. J Cardiopulm Rehabil Prev. 2021 Sep 1;41(5):336-340. IF 2.081.
15. ***Downregulation of DUOX1 function contributes to aging-related impairment of innate airway injury responses and accelerated senile emphysema.***  
Caspar Schiffers, Lennart K A Lundblad, Milena Hristova, Aida Habibovic, Christopher M Dustin, Nirav Daphtary, Minara Aliyeva, David J Seward, Yvonne M W Janssen-Heininger, Emiel F M Wouters, Niki L Reynaert, Albert van der Vliet.  
Am J Physiol Lung Cell Mol Physiol. 2021 Jul 1;321(1):L144-L158. IF: 4.659.
16. ***Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown.***  
Breyer MK, Breyer-Kohansal R, Hartl S, Kundi M, Weseslindtner L, Stiasny K, Puchhammer-Stöckl E, Schrott A, Födinger M, Binder M, Fiedler M, Wouters EFM, Burghuber OC. Sci Rep.2021 May 12;11, (1):10158 (2021). IF: 4.379.
17. ***Effects of Dynamic Hyperinflation on Left Ventricular Diastolic Function in Healthy Subjects - A Randomized Controlled Crossover Trial.***  
Urban MH, Mayr AK, Schmidt I, Grasmuk-Siegl E, Burghuber OC, Funk GC. Front Med (Lausanne). 2021 May 4;8:659108. IF: 4.468.
18. ***Downregulation of DUOX1 function contributes to aging-related impairment of innate airway injury responses and accelerated senile emphysema.***  
Schiffers C, Lundblad LKA, Hristova M, Habibovic A, Dustin CM, Daphtary N, Aliyeva M, Seward DJ, Janssen-Heininger YMW, Wouters EFM, Reynaert NL, van der Vliet A. Am J Physiol Lung Cell Mol Physiol. 2021 May 5. IF: 4.418.
19. ***Glutathionylation chemistry promotes interleukin 1 beta-mediated glycolytic reprogramming and pro-inflammatory signaling in lung epithelial cells.***  
Aboushousha R, Elko E, Chia SB, Manuel AM, van de Wetering C, van der Velden J, MacPherson M, Erickson C, Reisz JA, D'Alessandro A, Wouters EFM, Reynaert NL, Lam YW, Anathy V, van der Vliet A, Seward DJ, Janssen-Heininger YMW. FASEB J. 2021 May;35(5):e21525. IF: 4.966.
20. ***A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests.***  
Klausberger M, Duerkop M, Haslacher H, Wozniak-Knopp G, Cserjan-Puschmann M, Perkmann T, Lingg N, Aguilar PP, Laurent E, De Vos J, Hofner M, Holzer B, Stadler M,

Manhart G, Vierlinger K, Egger M, Milchram L, Gludovacz E, Marx N, Köppl C, Tauer C, Beck J, Maresch D, Grünwald-Gruber C, Strobl F, Satzer P, Stadlmayr G, Vavra U, Huber J, Wahrmann M, Eskandary F, Breyer MK, Sieghart D, Quehenberger P, Leitner G, Strassl R, Egger AE, Irsara C, Griesmacher A, Hoermann G, Weiss G, Bellmann-Weiler R, Loeffler-Ragg J, Borth N, Strasser R, Jungbauer A, Hahn R, Mairhofer J, Hartmann B, Binder NB, Striedner G, Mach L, Weinhäusel A, Dieplinger B, Grebien F, Gerner W, Binder CJ, Grabherr R. EBioMedicine. 2021 May;67:103348. IF: 8.143.

21. ***Healthcare and Societal Costs in Patients with COPD and Breathlessness after Completion of a Comprehensive Rehabilitation Program.***  
Verberkt CA, van den Beuken-van Everdingen MHJ, Dirksen CD, Schols JMGA, Vanfleteren LEGW, Franssen FME, Groenen MTJ, Wouters EFM, Janssen DJA. COPD. 2021 Apr;18(2):170-180 IF: 3.355.
22. ***Cost-effectiveness of sustained-release morphine for refractory breathlessness in COPD: A randomized clinical trial.***  
Verberkt CA, van den Beuken-van Everdingen MHJ, Dirksen CD, Schols JMGA, Wouters EFM, Janssen DJA. Respir Med. 2021;Apr;179:106330. IF: 4.084.
23. ***Frequency and functional translation of low muscle mass in overweight and obese patients with COPD.***  
Machado FVC, Spruit MA, Groenen MTJ, Houben-Wilke S, van Melick PP, Hernandez NA, Schols AMWJ, Pitta F, Wouters EFM, Franssen FME. Respir Res. 2021 Mar 25;22(1):93. IF: 4.916.
24. ***Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort.***  
Celli B, Locantore N, Yates JC, Bakke P, Calverley PMA, Crim C, Coxson HO, Lomas DA, MacNee W, Miller BE, Mullerova H, Rennard SI, Silverman EK, Wouters E, Tal-Singer R, Agusti A, Vestbo J. Eur Respir J. 2021 Mar 25;57(3):2001339. IF: 16.671.
25. ***Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients.***  
Hackner K, Buder A, Hochmair MJ, Strieder M, Grech C, Fabikan H, Burghuber OC, Errhalt P, Filipits M. Clin Med Insights Oncol. 2021 Feb 17;15:1179554921993072. IF: 1.077.
26. ***Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial.***  
Urban MH, Kreibich N, Gleiss A, Funk GC, Hartl S, Burghuber OC. Respirology. 2021 Feb;26(2):153-160. IF: 4.880.
27. ***Induction of dynamic hyperinflation by expiratory resistance breathing in healthy subjects - an efficacy and safety study.***  
Urban MH, Mayr AK, Schmidt I, Margulies E, Grasmuk-Siegl E, Burghuber OC, Funk GC. Exp Physiol. 2021 Feb;106(2):532-543. Epub 2020 Nov 23. IF: 2.431.
28. ***Downregulation of epithelial DUOX1 in chronic obstructive pulmonary disease.***  
Schiffers C, van de Wetering C, Bauer RA, Habibovic A, Hristova M, Dustin CM, Lambrichts S, Vacek PM, Wouters EF, Reynaert NL, van der Vliet A. JCI Insight. 2021 Jan

25;6(2):e142189.IF: 6.205.

29. **Reference charts for body composition parameters by dual-energy X-ray absorptiometry in European children and adolescents aged 6 to 18 years-Results from the Austrian LEAD (Lung, hEart, sociAl, boDy) cohort.**  
Ofenheimer A, Breyer-Kohansal R, Hartl S, Burghuber OC, Krach F, Schrott A, Franssen FME, Wouters EFM, Breyer MK. *Pediatr Obes.* 2021 Jan;16(1):e12695. IF: 3.429.

## 2020

30. **Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.**  
Frass M, Lechleitner P, Gründling C, Pirker C, Grasmuk-Siegl E, Domayer J, Hochmair M, Gaertner K, Duscheck C, Muchitsch I, Marosi C, Schumacher M, Zöchbauer-Müller S, Manchanda RK, Schrott A, Burghuber O. *Oncologist.* 2020;Dec;25(12):e1930-e1955. IF: 5.550.
31. **Incorporating Comprehensive Assessment Parameters to Better Characterize and Plan Rehabilitation for Persons with Chronic Obstructive Pulmonary Disease.**  
Augustin IML, Spruit MA, Franssen FME, Gaffron S, van Merode F, Wouters EFM. *J Am Med Dir Assoc.* 2020;21(12):1986-1991.e3. IF: 4.367.
32. **Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity.**  
Perkmann T, Perkmann-Nagele N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, Aletaha D, Sieghart D, Quehenberger P, Marculescu R, Mucher P, Strassl R, Wagner OF, Binder CJ, Haslacher H. *Clin Chem.* 2020 Nov 1;66(11):1405-1413. IF: 7.292.
33. **Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial.**  
Verberkt CA, van den Beuken-van Everdingen MHJ, Schols JMGA, Hameleers N, Wouters EFM, Janssen DJA. *JAMA Intern Med.* 2020 Oct 1;180(10):1306-1314. IF: 18.652.
34. **Results of the Austrian National Lung Cancer Audit.**  
Burghuber, OC, Kirchbacher K, Mohn-Staudner A, Hochmair M, Breyer M.-K, Studnicka M, Mueller M. R, Feurstein P, Schrott A, Lamprecht B, Eckmayr J, Renner F, Bolitschek J, Pohl W, Schenk P, Errhalt P, Cerkl P, Baumgartner B, Kneussl M, Hartl S. *Clin Med Insights Oncol.* 2020 Sep 10;14:1179554920950548. IF: 1.077.
35. **Reference values of body composition parameters and visceral adipose tissue (VAT) by DXA in adults aged 18-81 years-results from the LEAD cohort.**  
Ofenheimer A, Breyer-Kohansal R, Hartl S, Burghuber OC, Krach F, Schrott A, Wouters EFM, Franssen FME, Breyer MK. *Eur J Clin Nutr* 2020 Aug;74(8):1181-1191. IF: 3.291.

36. ***Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria - Results from the CLARA Project.***  
Horner A, Burghuber OC, Hartl S, Studnicka M, Merkle M, Olschewski H, Kaiser B, Wallner EM, Lamprecht B. *Int J Chron Obstruct Pulmon Dis.* 2020 Jul 12;15:1655-1663. IF: 3.157.
37. ***Factors Associated with Low Lung Function in Different Age Bins in the General Population.***  
Breyer-Kohansal R, Faner R, Breyer MK, Ofenheimer A, Schrott A, Studnicka M, Wouters EFM, Burghuber OC, Hartl S, Agusti A. *Am J Respir Crit Care Med* 2020 Jul 15;202(2):292-296. IF: 17.452.
38. ***Atrial fibrillation: a risk factor for unfavourable outcome in COVID-19? A case report.***  
Schnaubelt S, Breyer MK, Siller-Matula J, Domanovits H. *Eur Heart J Case Rep.* 2020 Jun 24;4(FI1):1-6. IF: 24.889.
39. ***Blood eosinophil count in the general population: typical values and potential confounders.***  
Hartl S, Breyer MK, Burghuber OC, Ofenheimer A, Schrott A, Urban MH, Agusti A, Studnicka M, Wouters EFM, Breyer-Kohansal R. *Eur Respir J.* 2020 May 14;55(5):1901874. IF: 12.339.
40. ***Marked differences in prediabetes- and diabetes-associated comorbidities between men and women-Epidemiological results from a general population-based cohort aged 6-80 years -The LEAD (Lung, hEart, sociAl, boDy) study.***  
Breyer MK, Ofenheimer A, Altziebler J, Hartl S, Burghuber OC, Studnicka M, Purin D, Heinzle C, Drexel H, Franssen FME, Wouters EFM, Harreiter J, Kautzky-Willer A, Breyer-Kohansal R. *Eur J Clin Invest.* 2020 Mar;50(3):e13207. IF: 3.481.

## 2019

41. ***The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study.***  
Breyer-Kohansal R, Hartl S, Burghuber OC, Urban M, Schrott A, Agusti A, Sigsgaard T, Vogelmeier C, Wouters E, Studnicka M, Breyer MK. *J Epidemiol* 2019 Aug 5;29(8):315–324. IF: 7.707.
42. ***EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.***  
Buder A, Setinek U, Hochmair MJ, Schwab S, Kirchbacher K, Keck A, Burghuber OC, Pirker R, Filipits M. *Target Oncol* 2019 Apr;14(2):197–203. IF: 4.036.
43. ***The European COPD audit: Adherence to guidelines, readmission risk and hospital care for acute exacerbations in Austria.***  
Breyer-Kohansal R, Hartl S, Breyer MK, Schrott A, Studnicka M, Neunhuserer D, Fulop G, Burghuber OC. *Wien Klin Wochenschr* 2019 Mar;131(5–6):97–103. IF: 1.704.

44. ***Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration.***  
Agusti A, Faner R, Donaldson G, Heuvelin E, Breyer-Kohansal R, Melén E, Maitland-van der Zee AH, Vestbo J, Allinson JP, Vanfleteren LEGW, van den Berge M, Adcock IM, Lahousse L, Brusselle G, Wedzicha JA; on behalf of the CADSET Clinical Research Collaboration; Current members of the CADSET Clinical Research Collaboration. Eur Respir J. 2019 Mar 18;53(3):1900217. IF: 12.339.
45. ***Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.***  
Hochmair MJ, Buder A, Schwab S, et al. Target Oncol 2019 Feb;14(1):75–83. IF: 4.036.
46. ***Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).***  
Halmos B, Tan E-H, Soo RA, et al. Lung Cancer 2019 Jan;127:103–11. IF: 4.702.

## 2018

47. ***Fatale immunmedierte organisierende Pneumonie unter Pembrolizumab - Therapie eines pulmonalen Adenokarzinoms.***  
Gasser S, Krenbek D, Hochmair M. Rofo. 2018 Dec;190(12):1161–3.
48. ***First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.***  
Horn L, Mansfield AS, Szczesna A, et al. N Engl J Med 2018 Dec 6;379(23):2220–9.
49. ***Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer.***  
Camidge DR, Kim HR, Ahn MJ, et al. N Engl J Med 2018 Nov;379(21):2027–39.
50. ***Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study***  
Hochmair MJ, Morabito A, Hao D, et al.. Futur Oncol 2018 Nov;14(27):2861–74.
51. ***Long-term outcomes after acute hypercapnic COPD exacerbation: First-ever episode of non- invasive ventilation.***  
Fazekas AS, Aboulghaith M, Kriz RC, Urban M, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, Funk GC. Wien Klin Wochenschr. 2018 Oct;130(19-20):561-568.
52. ***Valve therapy in patients with emphysematous type of chronic obstructive pulmonary disease (COPD): from randomized trials to patient selection in clinical practice.***  
Valipour A. J Thorac Dis 2018 Aug;10(S23):S2780–96.
53. ***Long-term safety of bilateral targeted lung denervation in patients with COPD.***  
Valipour A, Asadi S, Pison C, et al. Int J Chron Obstruct Pulmon Dis 2018 Jul 16;13:2163–2172.
54. ***Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.***

Buder A, Hochmair MJ, Schwab S, et al. J Thorac Oncol 2018 Jun;13(6):821–30.

55. **Phenotypes of COPD in an Austrian population: National data from the POPE study.**  
Reiger G, Zwick R, Lamprecht B, Kähler C, Burghuber OC, Valipour A. Wien Klin Wochenschr 2018 Jun;130(11–12):382–9. IF: 1.704.
56. **Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung.**  
Brcic L, Stanzer S, Krenbek D, et al. Virchows Arch 2018 Apr;472(4):589–98.
57. **Do doctors understand the test characteristics of lung cancer screening?**  
Schmidt R, Breyer MK, Breyer-Kohansal R, Urban M, Funk GC. Wien Klin Wochenschr. 2018 Apr;130(7-8):238-24.

## 2017

58. **Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.**  
Hochmair MJ, Schwab S, Burghuber OC, Krenbek D, Prosch H. Lung Cancer 2017 Nov;113:4–6.
59. **How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?**  
Beeh KM, Burgel P-R, Franssen FME, et al. Am J Respir Crit Care Med 2017 Jul 15;196(2):139–149.
60. **First use of Amplatzer device for bronchopleural fistula after lung transplantation**  
Gómez López A, Luján RG, De Pablo Gafas A, Valipour A et.al. Thorax. 2017 Jul;72(7):668-670.
61. **Accuracy of COPD Diagnosis During an Admission: The European Perspective.**  
Lopez-Campos JL, Castro-Acosta A, Pozo-Rodriguez F, Hartl S, Roberts CM. Chest 2017 Jun;151(6):1396–1397.
62. **Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study.**  
Koblizek V, Milenkovic B, Barczyk A, et al. Eur Respir J 2017 May 11;49(5):1601446.
63. **Treatment of COPD Exacerbation in Switzerland: Results and Recommendations of the European COPD Audit.**  
Buess M, Schilter D, Schneider T, et al. Respiration 2017;94(4):355–365.
64. **OLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort.**  
Tudoric N, Koblizek V, Miravitlles M, et al. Eur Respir J 2017 Apr 26;49(4):1602518.



65. ***Increased brachial intima-media thickness is associated with circulating levels of asymmetric dimethylarginine in patients with COPD.***  
Urban M, Eickhoff P, Funk G-C, Burghuber OC, Wolzt M, Valipour A. *Int J Chron Obstruct Pulmon Dis* 2017 Jan 4;12:169–176.
66. ***Bronchoscopic Thermal Vapour Ablation: Hot Stuff to Treat Emphysema Patients!***  
Valipour A. *Arch Bronconeumol* 2017 Jan;53(1):1–2.

## 2016

67. ***Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study.***  
Valipour A, Slebos D-JJ, Herth FJ, et al. *Am J Respir Crit Care Med* 2016 Nov 1;194(9):1073–1082.
68. ***Endobronchial Valves for Endoscopic Lung Volume Reduction: Best Practice Recommendations from Expert Panel on Endoscopic Lung Volume Reduction.***  
Gompelmann D, Eberhardt R, Schuhmann M, Valipour A, Shah PL, Herth FJF, Kontogianni K. *Respiration* 2016;92(6):397-403.
69. ***Endoscopic valve therapy for emphysema: Patient selection as the Holy Grail to success.***  
Valipour A. *Respirology* 2016 Oct;21(7):1148–9.
70. ***Thermal vapour ablation to reduce segmental volume in patients with severe emphysema: STEP-UP 12 month results.***  
Shah PL, Gompelmann D, Valipour A, et al. *Lancet Respir Med* 2016 Sep;4(9):e44–e45.
71. ***Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis?***  
Hartl S, Lopez-Campos JL. *Eur Respir J* 2016 Jul;48(1):281–2.
72. ***Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial.***  
Herth FJF, Valipour A, Shah PL, et al. *Lancet Respir Med* 2016 Mar;4(3):185–93.
73. ***Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit.***  
Ruparel M, López-Campos JL, Castro-Acosta A, Hartl S, Pozo-Rodriguez F, Roberts CM. *ERJ Open Res* 2016 Mar;2(1):00034–2015.
74. ***POPE study: Rationale and methodology of a study to phenotype patients with COPD in central and Eastern Europe.***  
Zbozinkova Z, Barczyk A, Tkacova R, et al. *Int J COPD* 2016 Mar 22;11(1):611–22.
75. ***Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit.***

Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Eur Respir J 2016 Jan;47(1):113–21.

## 2015

76. ***The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit.***  
Saleh A, López-Campos JL, Hartl S, Pozo-Rodríguez F, Roberts CM. PLoS One 2015 Jul 27;10(7):e0134004.
77. ***Targeted lung denervation for moderate to severe COPD: a pilot study.***  
Slebos D-JJ, Klooster K, Koegelenberg CFNN, et al. Thorax 2015 May;70(5):411–9.
78. ***Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit.***  
López-Campos JL, Hartl S, Pozo-Rodríguez F, Roberts CM. PLoS One 2015 Apr 23;10(4):e0124374.
79. ***Patterns of Emphysema Heterogeneity.***  
Valipour A, Shah PL, Gesierich W, et al. Respiration 2015;90(5):402–11.
80. ***An acetate-buffered balanced crystalloid versus 0.9% saline in patients with end-stage renal disease undergoing cadaveric renal transplantation: A prospective randomized controlled trial.***  
Potura E, Lindner G, Biesenbach P, et al. Anesth Analg 2015 Jan;120(1):123–9.

## 2014

81. ***Prevalence of Metabolic Syndrome in COPD Patients and Its Consequences.***  
Breyer M-K, Spruit MA, Hanson CK, et al. PLoS One 2014 Jun 20;9(6):e98013.
82. ***Pneumothorax following Endobronchial Valve Therapy and Its Impact on Clinical Outcomes in Severe Emphysema.***  
Gompelmann D, Herth FJF, Slebos DJ, et al. Respiration 2014;87(6):485–91.
83. ***Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial.***  
Köhnlein T, Windisch W, Köhler D, et al. Lancet Respir Med 2014 Sep;2(9):698–705.
84. ***Impact of proton pump inhibitor use on magnesium homeostasis: a cross-sectional study in a tertiary emergency department.***  
Lindner G, Funk G-C, Leichtle AB, et al. Int J Clin Pract 2014;68(11):1352–7.
85. ***Evaporation of free water causes concentrational alkalosis in vitro.***  
Lindner G, Doberer D, Schwarz C, Schneeweiss B, Funk G-C. Wien Klin Wochenschr 2014;126(7–8):201–7. IF: 1.704.

86. ***D-dimer to rule out pulmonary embolism in renal insufficiency.***  
Lindner G, Funk GC, Pfortmueller CA, et al. Am J Med 2014;127(4):343–7.
87. ***Variability of hospital resources for acute care of COPD patients: the European COPD Audit.***  
Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM. Eur Respir J 2014;43(3):754–62.
88. ***Effectiveness and efficacy of minimally invasive lung volume reduction surgery for emphysema.***  
Pertl D, Eisenmann A, Holzer U, Renner A-T, Valipour A. GMS Health Technol Assess 2014;10:Doc01.
89. ***Electrolyte Disorders and In-Hospital Mortality during Prolonged Heat Periods: A Cross-Sectional Analysis.***  
Pfortmueller CA, Funk G-C, Leichtle AB, et al. PLoS One 2014;9(3):e92150.
90. ***Hypoglycemia is associated with increased mortality in patients with acute decompensated liver cirrhosis.***  
Pfortmueller CA, Wiemann C, Funk G-C, et al. J Crit Care 2014;29(2):316.e7-316.e12.
91. ***Differences in content and organisational aspects of pulmonary rehabilitation programmes.***  
Spruit MA, Pitta F, Garvey C, et al. Eur Respir J 2014;43(5):1326–37.
92. ***Soluble receptor of advanced glycation end-products and endothelial dysfunction in COPD.***  
Urban MH, Valipour A, Kiss D, Eickhoff P, Funk GC, Burghuber OC. Respir Med 2014;108(6):891–7.
93. ***Insulin resistance may contribute to vascular dysfunction in patients with chronic obstructive pulmonary disease.***  
Urban MH, Ay L, Funk GC, et al. Wien Klin Wochenschr 2014;126(3–4):106–12.
94. ***Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy.***  
Valipour A, Herth FJF, Burghuber OC, et al. Eur Respir J 2014;43(2):387–96.
95. ***Design of the randomized, controlled sequential staged treatment of emphysema with upper lobe predominance (STEP-UP) study.***  
Valipour A, Herth FJ, Eberhardt R, et al. BMC Pulm Med 2014;14(1):190.
96. ***Moving from the Oslerian paradigm to the postgenomic era: Are asthma and COPD outdated terms?***  
Vanfleteren LEGW, Kocks JWH, Stone IS, et al. Thorax 2014;69(1):72–9.

97. ***Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department: a cross-sectional analysis.***  
Arampatzis S, Funk G-C, Leichtle AB, et al. BMC Med 2013;11(1):83.
98. ***Diuretic-induced hyponatremia and osteoporotic fractures in patients admitted to the emergency department.***  
Arampatzis S, Gaetcke L-M, Funk G-C, et al. Maturitas 2013;75(1):81–6
99. ***Evaluation of 36 formulas for calculating plasma osmolality.***  
Fazekas AS, Funk G-C, Klobassa DS, et al. Intensive Care Med 2013;39(2):302–8.
100. ***Endoscopic One-Way Valve Implantation in Patients With Prolonged Air Leak and the Use of Digital Air Leak Monitoring.***  
Firlinger I, Stubenberger E, Müller MR, Burghuber OC, Valipour A. Ann Thorac Surg 2013;95(4):1243–9.
101. ***Prevalence and prognosis of COPD in critically ill patients between 1998 and 2008.***  
Funk GC, Bauer P, Burghuber OC, et al. Eur Respir J 2013;41(4):792–9.
102. ***The localized inflammatory response to bronchoscopic thermal vapor ablation.***  
Gompelmann D, Eberhardt R, Ernst A, et al. Respiration 2013;86(4):324–31.
103. ***Unmeasured anions are associated with short-term mortality in patients with hypoxic hepatitis.***  
Kneidinger N, Funk GC, Lindner G, Drolz A, Schenk P, Fuhrmann V. Wien Klin Wochenschr 2013;125(15–16):474–80.
104. ***High-Sensitive Troponin Measurement in Emergency Department Patients Presenting with Syncope: A Retrospective Analysis.***  
Lindner G, Pfortmueller CA, Funk G-C, Leichtle AB, Fiedler GM, Exadaktylos AK. PLoS One 2013;8(6):e66470.
105. ***Rising serum sodium levels are associated with a concurrent development of metabolic alkalosis in critically ill patients.***  
Lindner G, Schwarz C, Grüssing H, Kneidinger N, Fazekas A, Funk G-C. Intensive Care Med 2013;39(3):399–405.
106. ***European COPD Audit: Design, organisation of work and methodology.***  
Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM. Eur Respir J. 2013 Feb;41(2):270–6.
107. ***Diagnostic performance of high-sensitive troponin T in patients with renal insufficiency.***  
Pfortmueller CA, Funk GC, Marti G, et al. Am J Cardiol 2013;112(12):1968–72.
108. ***European hospital adherence to GOLD recommendations for chronic obstructive pulmonary disease (COPD) exacerbation admissions: Table 1.***

Roberts CM, Lopez-Campos JL, Pozo-Rodriguez F, Hartl S. *Thorax* 2013;68(12):1169–71.

## 2012

109. ***Characteristics, Symptoms, and Outcome of Severe Dysnatremias Present on Hospital Admission.***  
Arampatzis S, Frauchiger B, Fiedler G-M, et al. *Am J Med* 2012;125(11):1125.e1-1125.e7.
110. ***Geriatric urolithiasis in the emergency department: risk factors for hospitalisation and emergency management patterns of acute urolithiasis.***  
Arampatzis S, Lindner G, Irmak F, Funk G-C, Zimmermann H, Exadaktylos AK. *BMC Nephrol* 2012;13(1):117.
111. ***Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease: Results from the Cosmic Study.***  
Breyer M-K, Rutten EPA, Spruit MA, Hop WCJ, Postma DS, Wouters EFM. *Open J Respir Dis* 2012;02(03):63–72.
112. ***Dysregulated adipokine metabolism in chronic obstructive pulmonary disease.***  
Breyer M-K, Rutten EPA, Locantore NW, Watkins ML, Miller BE, Wouters EFM. *Eur J Clin Invest* 2012;42(9):983–91.
113. ***Carboxyhemoglobin levels in medical intensive care patients: a retrospective, observational study.***  
Fazekas AS, Wewalka M, Zauner C, Funk G-C. *Crit Care* 2012;16(1):R6.
114. ***Efficacy of bronchoscopic thermal vapor ablation and lobar fissure completeness in patients with heterogeneous emphysema.***  
Gompelmann D, Heussel CP, Eberhardt R, et al. *Respiration* 2012;83(5):400–6.
115. ***The European COPD Audit: a pilot experience of 16 European countries.***  
Hartl S. *Pneumonol Alergol Pol* 2012;80(6):501–4.
116. ***Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort.***  
Herth FJF, Noppen M, Valipour A, et al. *Eur Respir J* 2012;39(6):1334–42.
117. ***Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema. Int J Chron.***  
Herth FJ, KM B, Egan JJ, et al. *Obstruct Pulmon Dis* 2012;7:397.
118. ***Osmotic diuresis due to urea as the cause of hypernatraemia in critically ill patients.***  
Lindner G, Schwarz C, Funk G-C. *Nephrol Dial Transplant* 2012;27(3):962–7.
119. ***Effect of fissure integrity on lung volume reduction using a polymer sealant\* in advanced emphysema.***  
Magnussen H, Kramer MR, Kirsten A-M, et al. *Thorax* 2012;67(4):302–8.

120. ***Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema.***

Snell G, Herth FJF, Hopkins P, et al. *Eur Respir J* 2012;39(6):1326–33.

121. ***Physiological Modeling of Responses to Upper Versus Lower Lobe Lung Volume Reduction in Homogeneous Emphysema.***

Valipour A, Kramer MR, Stanzel F, et al. *Front Physiol* 2012;3:387.

## 2011

122. ***Gender differences in the adipose secretome system in chronic obstructive pulmonary disease (COPD): A pivotal role of leptin.***

Breyer M-K, Rutten EPA, Vernooij JHJ, et al. *Respir Med* 2011;105(7):1046–53.

123. ***Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system.***

Faybik P, Hetz H, Mitterer G, et al. *Crit Care Med* 2011;39(2):273–9.

124. ***Long-term non-invasive ventilation in COPD after acute-on-chronic respiratory failure.***

Funk G-C, Breyer M-K, Burghuber OC, et al. *Respir Med* 2011;105(3):427–34.

125. ***Whole Body Hyperthermia by Extracorporeal Circulation in Spontaneously Breathing Sarcoma Patients: Hemodynamics and Oxygen Metabolism.***

Locker GJ, Fuchs E-M, Worel N, et al. *Int J Artif Organs* 2011;34(11):1085–94.

126. ***Non-CPAP therapies in obstructive sleep apnoea.***

Randerath WJ, Verbraecken J, Andreas S, et al. *Eur Respir J* 2011;37(5):1000–28.

127. ***Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease.***

Valipour A, Lavie P, Lothaller H, Mikulic I, Burghuber OC. *Sleep Med* 2011;12(4):367–72.

## 2010

128. ***Nordic Walking improves daily physical activities in COPD: a randomised controlled trial.***

Breyer M-K, Breyer-Kohansal R, Funk G-C, et al. *Respir Res* 2010;11(1):112.

129. ***Incidence and outcome of weaning from mechanical ventilation according to new categories.***

Funk G-C, Anders S, Breyer M-K, et al. *Eur Respir J* 2010;35(1):88–94.

130. ***Intensive care-acquired hypernatremia after major cardiothoracic surgery is associated with increased mortality.***

Lindner G, Funk G-C, Lassnigg A, et al. *Intensive Care Med* 2010;36(10):1718–23.

131. ***Abdominal fat mass contributes to the systemic inflammation in chronic obstructive pulmonary disease.***

Rutten EPA, Breyer MK, Spruit MA, et al. Clin Nutr 2010;29(6):756–60.

132. ***Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines.***

Walch A, Meshkat M, Vogelsang H, et al. J Crohn's Colitis 2010;4(4):398–404.

## 2009

133. ***Highly elevated C-reactive protein levels in obese patients with COPD: A fat chance?***

Breyer M-K, Spruit MA, Celis APM, Rutten EPA, Janssen PP, Wouters EFM. Clin Nutr 2009;28(6):642–7.

134. ***Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study.***

Cekici L, Valipour A, Kohansal R, Burghuber OC. Br J Clin Pharmacol 2009;67(4):394–402.

135. ***BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD – a cross-sectional study.***

Funk G-C, Kirchheiner K, Chris Burghuber O, Hartl S. Respir Res 2009;10(1):1.

136. ***Measuring FEV6 for detecting early airway obstruction in the primary care setting.***

Kaufmann M, Hartl S, Geyer K, Breyer MK, Burghuber OC. Respiration 2009;78(2):161–

137. ***The Natural History of Chronic Airflow Obstruction Revisited.***

Kohansal R, Martinez-Cambor P, Agustí A, Buist AS, Mannino DM, Soriano JB. Am J Respir Crit Care Med 2009;180(1):3–10.

138. ***Investigating the Natural History of Lung Function: facts, pitfalls, and opportunities.***

Kohansal R, Soriano JB, Agusti A. Chest 2009;135(5):1330–41.

139. ***COPD and Osteoporosis: Detection and Grading of Vertebral Fractures on Lateral Chest Radiography.***

Oschatz E, Prosch H, Kohansal R, Valipour A, Mostbeck G. J Thorac Imaging 2009;24(3):212–5.

140. ***Comparison of daily physical activity between COPD patients from Central Europe and South America.***

Pitta F, Breyer MK, Hernandez NA, et al. Respir Med 2009;103(3):421–6.

141. ***Der Effekt von einem Jahr ambulanter pneumologischer Rehabilitation auf Patienten mit COPD.***

Zwicky RH, Burghuber OC, Dovjak N, et al. Wien Klin Wochenschr 2009;121(5–6):189–95.

## 2008

142. **Determinants of Systemic Vascular Function in Patients with Stable Chronic Obstructive Pulmonary Disease.**  
Eickhoff P, Valipour A, Kiss D, et al. Am J Respir Crit Care Med 2008;178(12):1211–8.
143. **Left Ventricular Diastolic Dysfunction in Patients With COPD in the Presence and Absence of Elevated Pulmonary Arterial Pressure.**  
Funk G-C, Lang I, Schenk P, Valipour A, Hartl S, Burghuber OC. Chest 2008;133(6):1354–9.
144. **Ist das obstruktive Schlafapnoesyndrom ein Risikofaktor für das metabolische Syndrom?**  
Valipour, Arschang, Ruis M, Burghuber OC. J für Hypertonie 2008;12(2):31–3.
145. **Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease.**  
Valipour A, Schreder M, Wolzt M, et al. Clin Sci 2008;115(7):225–32.
146. **Abnormal pulmonary arterial pressure limits exercise capacity in patients with COPD.**  
Vonbank K, Funk GC, Marzluf B, et al. Wien Klin Wochenschr 2008;120(23–24):749–55.

## 2007

147. **Gas concentrations in expired air during basic life support using different ratios of compression to ventilation.**  
Eisenburger P, Funk GC, Burda G, Sterz FR, Laggner AN, Herkner H. Resuscitation 2007;73(1):115–22.
148. **Correlation of calculated indices of insulin resistance (QUICKI and HOMA) with the euglycaemic hyperinsulinaemic clamp technique for evaluating insulin resistance in critically ill patients.**  
Holzinger U, Kitzberger R, Fuhrmann V, Funk GC, Madl C, Ratheiser K. Eur J Anaesthesiol 2007;24(11):966–70.
149. **Acute phase proteins do not account for unmeasured anions in critical illness.**  
Kneidinger N, Lindner G, Fuhrmann V, et al. Eur J Clin Invest 2007;37(10):820–5.
150. **Hypernatremia in the Critically Ill Is an Independent Risk Factor for Mortality.**  
Lindner G, Funk GC, Schwarz C, et al. Am J Kidney Dis 2007;50(6):952–7.
151. **End-of-life decision-making in respiratory intermediate care units: A European survey.**  
Nava S, Sturani C, Hartl S, et al. Eur Respir J 2007;30(1):156–64.
152. **Gender-related differences in symptoms of patients with suspected breathing disorders in sleep: A clinical population study using the Sleep Disorders Questionnaire.**  
Valipour A, Lothaller H, Rauscher H, Zwick H, Burghuber OC, Lavie P. Sleep 2007;30(3):312–9.

## 2006-2003



153. ***Hepatopulmonary Syndrome in Patients With Hypoxic Hepatitis.***  
Fuhrmann V, Madl C, Mueller C, et al. *Gastroenterology* 2006;131(1):69–75.
154. ***Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection.***  
Kramer L, Hofer H, Bauer E, et al. *AIDS* 2005;19(Suppl 3):S85–92.
155. ***Verminderung von Hautdefekten bei Bauchlagerung bei beatmeten Intensivpatienten durch das prone-head-support-system: Eine Pilotstudie.***  
Prebio M, Katz-Papatheophilou E, Heindl W, Gelbmann H, Burghuber OC. *Wien Klin Wochenschr* 2005;117(3):98–105.
156. ***Bronchoscopy-Guided Topical Hemostatic Tamponade Therapy for the Management of Life-Threatening Hemoptysis.***  
Valipour A, Kreuzer A, Koller H, Koessler W, Burghuber OC. *Chest* 2005;127(6):2113–8.
157. ***Heart rate variability and spontaneous baroreflex sequences in supine healthy volunteers subjected to nasal positive airway pressure.***  
Valipour A, Schneider F, Kössler W, Saliba S, Burghuber OC. *J Appl Physiol* 2005;99(6):2137–43.
158. ***Platelet aggregation and blood rheology in severe sepsis/septic shock: relation to the Sepsis-related Organ Failure Assessment (SOFA) score.***  
Alt E, Amann-Vesti BR, Madl C, Funk G, Koppensteiner R. *Clin Hemorheol Microcirc* 2004;30(2):107–15.
159. ***Provisions for long-term at home ventilated patient: consensus recommendations of the Austrian Society for Lung Diseases and Tuberculosis.***  
Hartl S, Heindl W, Lahrmann H, et al. *Wien Klin Wochenschr* 2004;116 Suppl(3):1–20.
160. ***Non-Invasive Pressure Support Ventilation in Patients with Respiratory Failure due to Severe Acute Cardiogenic Pulmonary Edema.***  
Valipour A, Cozzarini W, Burghuber OC. *Respiration* 2004;71(2):144–51.
161. ***Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing.***  
Valipour A, Litschauer B, Mittermayer F, Rauscher H, Burghuber OC, Wolzt M. *Respir Med* 2004;98(12):1180–6.
162. ***Electrophysiological assessment of the afferent sensory pathway in cardiac arrest survivors.***  
Bauer E, Funk G-C, Gendo A, et al. *Eur J Clin Invest* 2003;33(4):283–7.
163. ***Measurement of Changes in Cytochrome Oxidase Redox State During Obstructive Sleep Apnea Using Near-Infrared Spectroscopy.***  
McGown AD, Makker H, Elwell C, Rawi PG Al, Valipour A, Spiro SG. *Sleep* 2003;26(6):710–6.

164. ***Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.***

Petkov V, Mosgoeller W, Ziesche R, et al. J Clin Invest 2003;111(9):1339–46.

165. ***Long-term Treatment With Oral Sildenafil in Addition to Continuous IV Epoprostenol in Patients With Pulmonary Arterial Hypertension.***

Stiebellehner L, Petkov V, Vonbank K, et al. Chest 2003;123(4):1293–5.

## Reviews, editorials, guidelines, books

1. ***Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan***  
Alvar Agustí, Erik Melén, Dawn L DeMeo, Robab Breyer-Kohansal, Rosa Faner  
Lancet Respir Med. 2022 May;10(5):512-524.Epub 2022 Apr 12.
2. ***Spirometry: The Indefinite Search for Gold.***  
Wouters EFM, Breyer-Kohansal R.  
Chest. 2022 Mar;161(3):593-594.
3. ***Take a breath – Is it time to re-think how we diagnose COPD?***  
Wouters EFM, Breyer M.  
Research Outreach 2022 Feb; Issue 128:78-79.
4. ***Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis.***  
Benson VS, Hartl S, Barnes N, Galwey N, Van Dyke MK, Kwon N.  
Eur Respir J. 2022 Jan 13;59(1):2004590. IF: 16.671.
5. ***Redox Dysregulation in Aging and COPD: Role of NOX Enzymes and Implications for Antioxidant Strategies.***  
Schiffers C, Reynaert NL, Wouters EFM, van der Vliet A.  
Antioxidants (Basel). 2021 Nov 11;10(11):1799.
6. ***The prevalence and related factors of fatigue in patients with COPD: a systematic review.***  
Ebadi Z, Goërtz YMJ, Van Herck M, Janssen DJA, Spruit MA, Burtin C, Thong MSY, Muris J, Otker J, Looijmans M, Vlasblom C, Bastiaansen J, Prins J, Wouters EFM, Vercoulen JH, Peters JB. Eur Respir Rev. 2021 Apr 13;30(160):200298.
7. ***COPD Diagnosis: Time for Disruption.***  
Wouters EFM, Breyer MK, Breyer-Kohansal R, Hartl S.  
J Clin Med. 2021 Oct 11;10(20):4660.
8. ***Pre-Chronic Obstructive Pulmonary Disease: Toward the Limits of the Spirometric Funnel.***  
Wouters EFM. Am J Respir Crit Care Med. 2021 Jul 1;204(1):112. IF: 21.405.
9. ***Glutathione S-transferases and their implications in the lung diseases asthma and chronic obstructive pulmonary disease: Early life susceptibility?***  
van de Wetering C, Elko E, Berg M, Schiffers CHJ, Stylianidis V, van den Berge M, Nawijn MC, Wouters EFM, Janssen-Heininger YMW, Reynaert NL.  
Redox Biol. 2021 Jul;43:101995.
10. ***Lung Cancer in Austria.***  
Pirker R, Prosch H, Popper H, Klepetko W, Dieckmann K, Burghuber OC, Klikovits T, Hoda MA, Zöchbauer-Müller S, Filipits M. J Thorac Oncol. 2021 May;16(5):725-733.

11. ***Transitioning from infancy to adulthood: a black box full of opportunities.***  
Agusti A, Breyer-Kohansal R, Faner R. Eur Respir J. 2021 Mar 4;57(3):2003997.
12. ***Skin autofluorescence: early sign of lung function deterioration?***  
Wouters EFM, Reynaert NL. ERJ Open Res. 2020 Jul 20;6(2):00368-2020.
13. ***Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.***  
Hochmair M. Target Oncol 2018 Jun;13(3):269–85.
14. ***Correction to: Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.***  
Hochmair MJ. Target Oncol 2018;13(5):667–667.
15. ***Chronisch obstruktive Lungenerkrankung (COPD).***  
Urban M, Burghuber OC. Wiener Klin Wochenschrift Educ 2018;13(1–4):29–47.
16. ***Bronchoscopic Thermal Vapor Ablation: Best Practice Recommendations from an Expert Panel on Endoscopic Lung Volume Reduction.***  
Gompelmann D, Shah PL, Valipour A, Herth FJF. Respiration 2018;95(6):1–9.
17. ***Inhaled therapies in patients with moderate COPD in clinical practice: Current thinking.***  
Ariel A, Altraja A, Belevskiy A, et al. Int J Chron Obstruct Pulmon Dis. 2017 Dec 21;13:45-56.
18. ***Nichtinvasive und invasive außerklinische Beatmung beim chronisch respiratorischen Versagen.***  
Schenk P, Eber E, Funk G-C, et al. Wien Klin Wochenschr 2016;128(S1):1–36.
19. ***An update on the efficacy of endobronchial valve therapy in the management of hyperinflation in patients with chronic obstructive pulmonary disease.***  
Valipour A, Burghuber OC. Ther Adv Respir Dis 2015;9(6):294–301.
20. ***A review of the value of innovation in inhalers for COPD and asthma.***  
Virchow JC, Akdis CA, Darba J, et al. J Mark Access Heal Policy 2015;3(1):28760.
21. ***Lungenkrankheiten im Zusammenhang mit dem Rauchen (außer Lungenkrebs und COPD).***  
Burghuber OC, Urban MH, Hartl S. Atemwegs- und Lungenkrankheiten 2015;41(8):364–71.
22. ***Ambulatory management of primary spontaneous pneumothorax: the good is (not always) the enemy of the better (evidence).***  
Valipour A. Eur Respir J 2014;43(2):334–6.

23. **Expert Statement: Pneumothorax Associated with Endoscopic Valve Therapy for Emphysema - Potential Mechanisms, Treatment Algorithm, and Case Examples.**  
Valipour A, Slebos D-J, de Oliveira HG, et al. Respiration 2014;87(6):513–21.
24. **Adiposity in COPD.**  
Breyer M-K. Maastricht University, the Netherlands; 2013.
25. **Husten – Atemnot – COPD.**  
Hartl S, Netz M, Breyer M-K, Breyer-Kohansal R. Med Media Verlag; 2012.
26. **Pros and Cons of Humidification for CPAP Therapy in the Treatment of Sleep Apnea.**  
In: Esquinas Rodriguez AM, editor. Humidification in the Intensive Care Unit. Valipour A. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. p. 109–13.
27. **Komorbiditäten bei COPD – Entzündung und antiinflammatorische Therapie.**  
Burghuber OC, Breyer M, Funk G, Vogelmeier C. Bremen, London, Boston. Uni-Med; 2012.
28. **Kardiale Komorbidität bei COPD.**  
Valipour A. Atemwegs- und Lungenkrankheiten 2011;2(37):48–50.
29. **European Respiratory Society MD PhD programme in respiratory science.**  
Eickelberg O, Laurent G, Nicod LP, Hartl S, Siafakas NM. Eur Respir J 2010;36(2):229–30.
30. **Humidifiers during non-invasive ventilation - key topics and practical implications.**  
Esquinas Rodriguez AM, Scala R, Soroksky A, et al. Crit Care 2011;16(1):203.
31. **Chronic Obstructive Pulmonary Disease Exacerbations: Better Standards – Better Prognosis?**  
Hartl S. Respiration 2011;82(4):317–9.
32. **Schlafatemstörungen.**  
Valipour A, Burghuber OC. Wiener Klin Wochenschrift Educ 2009;4(1):15–32.
33. **Knowing chronic obstructive pulmonary disease by heart: Cumulating evidence of systemic vascular dysfunction.**  
Burghuber OC, Valipour A. Am J Respir Crit Care Med 2009;180(6):487–8.
34. **Knowing Chronic Obstructive Pulmonary Disease by Heart.**  
Burghuber OC, Valipour A. Am J Respir Crit Care Med 2009;180(6):487–8.
35. **Nicht invasive Beatmung (NIV).**  
Hartl S, Breyer M. Wiener Klin Wochenschrift Educ 2009;4(3):113–21.
36. **Co-morbid manifestations in COPD.**  
Wouters EFM, Celis MPM, Breyer MK, Rutten EPA, Graat-Verboom L, Spruit MA. Respir Med COPD Updat 2007;3(4):135–51.

37. ***Atemphysiotherapie bei CVI unter Berücksichtigung der NIV – Optionen. In: Schönhofer B, editor. Nicht-invasive Beatmung - Grundlagen und moderne Praxis.***  
Hartl S, Schmidt I. Bremen, London, Boston: Uni-Med; 2006. p. 178–81.
38. ***The diagnosis of COPD.***  
Hartl S, Burghuber OC. Wien Klin Wochenschr 2005;155(5–6):90–4.
39. ***Chronisch obstruktive Lungenerkrankung.***  
Burghuber OC. Wien Klin Wochenschr 2005;155(5–6):77–77.
40. ***Untersuchung des Lungenkreislaufes mittels Rechtsherzkatheter: Positionspapier des Kardiopulmonalen Arbeitskreises der Österreichischen Gesellschaft für Pneumologie und der Österreichischen Gesellschaft für Kardiologie.***  
Schenk P, Stiebellehner L, Burghuber OC, Kneussl M, Lang IM. Wien Klin Wochenschr 2005;117(18):651–62.
41. ***State of the Art.***  
Burghuber OC. COPD - Osterr Arzteztg 2005;9.
42. ***Pulmonary embolism: Clinical features. In: Albert A, Spiro S, Jett J, editors.***  
Burghuber OC. Clinical Respiratory Medicine. Mosby; 2004.
43. ***Non-invasive pressure support ventilation in patients with acute cardiogenic pulmonary edema: a critical appraisal.***  
Valipour A, Burghuber O. In: Esquinas A, Volsko T, Scala R, editors. International Respiratory Care Clinics and Technology. Mason / Grupo Aulamedica; 2003.
44. ***Diffuse interstitielle Lungenerkrankungen mit besonderer Berücksichtigung des rheumatischen Formenkreises.***  
Koller HK, Burghuber OC. Z Rheumatol 2003;62(2):122–35.
45. ***Konsensus-Empfehlungen der Arbeitsgruppe Pulmonalarterielle Hypertension der Österreichischen Gesellschaft für Lungenerkrankungen und Tuberkulose.***  
Block LH, Burghuber OC, Hartl S, Zwick H. Wien Klin Wochenschr 2003;115(10):351.
46. ***Austrian Society of Lung Diseases and Tuberculosis: Consensus on Management of Chronic Obstructive Lung Diseases (COPD). 1999 Revision***  
Block LH, Burghuber OC, Hartl S, Zwick H.  
Wien Klin Wochenschr 2000 Jan 14;112(1):41-5.